RSV Bronchiolitis Clinical Trial
Official title:
Pilot Study: Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis
This trial is a proof-of-concept pilot study aim to investigate the biologic and clinical
effects of early azithromycin treatment in children hospitalized with Respiratory Syncytial
Virus (RSV) bronchiolitis.
HYPOTHESES
In infants hospitalized with RSV bronchiolitis, azithromycin therapy (compared to placebo)
will result in:
1. Decreased concentrations of inflammatory mediators (IL-8 as primary outcome) in serum
and nasal wash measured on day 8 after randomization.
2. A smaller proportion of participants with recurrent (≥2) wheezing episodes during weeks
3-52 following randomization.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04144816 -
Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants
|
||
| Active, not recruiting |
NCT03627572 -
RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants
|
||
| Terminated |
NCT00361452 -
Acoustic Assessment of Nebulized Epinephrine Versus Albuterol for RSV Bronchiolitis- a Double Blind Study
|
Phase 4 |